"Questions of valuation underpin many of the critical strategic decisions that biopharma executives make daily. More deals are being done at earlier development stages and in emerging markets—situations where more judgment is required because traditional valuation models are less effective. In today's volatile capital markets shareholders demand increased transparency into capital allocation and investment policies. Yet very few companies are uniformly competent either at technical valuation analysis or at managing the process. This panel will provide
practical insights on how to get the numbers and models right and how to interpret and apply the output as well as address valuation issues underlying the key questions of how much we should pay for acquisitions in emerging markets and how we ensure our public stock price reflects our intrinsic value."

Objective1: Prepare for the main risks and challenges presented by emerging markets.

Objective2: Understand actionable best practices and insights to help build organizational capabilities and improve deal processes.

Objective3: Learn from other industries what contributes to success and failure in emerging markets transactions.